Missing details in trial protocols slow pharmacy start-up

A study examined how complete the information in clinical trial protocols and pharmacy manuals is for investigational drug services. Researchers reviewed the latest documents for trials active on April 14, 2023, at a 500-bed mother-child university health center and assessed details such as prohibited medications, dosing, storage, concentration, packaging, and preparation. Among 60 trials and 83 investigational products, pharmacy manuals were more often provided by commercial sponsors than institutional sponsors. Several important items were frequently missing, including lists of prohibited medications, maximum doses, storage requirements, concentrations, and beyond-use dates after preparation. The authors conclude that gaps in documentation may slow pharmacy start-up and underline the need for better collaboration to support safety and data integrity.

What the study examined

This study looked at how complete trial protocols and pharmacy manuals are when used by investigational drug services. The review covered the most recent documents for clinical trials open for recruitment as of April 14, 2023, at a 500-bed mother-child university health center.

Evaluators checked whether documents included information important for handling investigational products, such as prohibited medications, dosing, storage, concentration, packaging, and preparation details.

Key findings

Sixty trials and 83 investigational products were included in the review. Most trials were phase 3 and most targeted pediatric populations.

• Pharmacy manuals were more frequently available from commercial sponsors (92%) than from institutional sponsors (54%), a difference that was statistically significant.
• Several key elements were often missing from the documents: a list of specific prohibited medications was absent for many products, maximum dose information was not always present, and details about storage and concentration were frequently lacking.
• Information needed after preparation—such as beyond-use dates—was missing in a notable portion of cases, and items like rounding rules and packaging dimensions were rarely included.

Why it matters

Complete and clear trial documentation supports timely pharmacy start-up and helps ensure participant safety and data integrity. When essential details are missing, pharmacies may face delays or uncertainty in how to handle investigational products.

The observed gaps point to a need for stronger collaboration between sponsors and investigational drug services to produce more comprehensive protocols and manuals that include the practical information pharmacies require.